Ligand Pharmaceuticals Incorporated - LGND Earnings per share for the trailing year

Risks for Ligand Pharmaceuticals (LGND) are limited by a patent licensing model with minimal marketing expenditures. This chart of the net income per share YoY ttm growth rate visualizes this stability, where 8.40 serves as the current metric level. The business's protection by hundreds of drug delivery patents guarantees multi-year royalties, while profits from partner cancer blockbusters ensure high asset margins.
ligand.com - analytical breakdowns and key metrics (LGND)

The business model of Ligand Pharmaceuticals (LGND) is based on high-margin royalties and the licensing of Captisol platforms, which makes earnings sensitive to one-time partner payments. The trend in trailing twelve months (ttm) earnings per share growth cleanses this stream of GAAP/Non-GAAP accounting distortions, allowing investors to assess the real profitability trend and eliminate the risk of overvaluing the asset due to artificially inflated adjustments.